The vanguard
08/25/2020 - 8:36
- Clarín.com
- World
An experimental vaccine against the coronavirus that is being developed by the University of Oxford and AstraZeneca could be presented to regulators this year if scientists can collect enough data , said the director of the Oxford Vaccine Group .
"It is possible that if the cases accumulate quickly in clinical trials, we could have that data before the regulators this year, and then there would be a process that they would go through to do a full evaluation of the data," Andrew Pollard told the Associated Press. BBC.
The Oxford vaccine showed promise in the first human trial when it produced an immune response, reaffirming its position as a leading candidate in the race to produce a vaccine against a disease that has crippled the world economy.
It is the vaccine that Argentina plans to develop together with Mexico to later be distributed in the region.
Laboratory technician works at mAbxience, in Garin, Argentina. Photo: AP
The trial made headlines earlier this week when the Financial Times reported that the Trump administration was considering speeding up the vaccine for use in the United States ahead of the Nov.3 election.
Emergency authorization
One option being explored would involve the US Food and Drug Administration (FDA) granting an "emergency use authorization" in October to the potential vaccine, the FT said.
"The process of going through emergency use authorization in an emergency is well established, but it still involves having carefully conducted data ... and evidence that it really works," said Pollard.
On the other hand, AstraZeneca has indicated this Tuesday that it has begun to test an antibody-based treatment for the prevention and treatment of COVID-19, administering doses to the first participants, a news that adds to recent signs of progress in the possible medical solutions of the disease.
Look also
Coronavirus in the World: photos of life in times of pandemic
The British drugmaker said the early-phase trial would assess whether AZD7442 , a combination of two monoclonal antibodies (mAbs), was safe and tolerable in up to 48 healthy participants aged 18 to 55 years.
If the UK trial has a positive reading, AstraZeneca said it would proceed with larger mid-to-late stage trials to test AZD7442 as a preventive treatment for the disease and as a drug for patients suffering from it.
AP